ViroGates A/S (VIRO.CO)

DKK 13.2

(0.76%)

Market Cap (In DKK)

102.09 Million

Revenue (In DKK)

6.98 Million

Net Income (In DKK)

-12.09 Million

Avg. Volume

3102.00

Currency
DKK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.98-31.0
PE
-
EPS
-
Beta Value
0.78
ISIN
DK0061030574
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Jakob Knudsen
Employee Count
-
Website
https://www.virogates.com
Ipo Date
2018-06-26
Details
ViroGates A/S develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging; and suPARnostic ELISA that provides fully quantitative results. Its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was incorporated in 2000 and is headquartered in Birkerød, Denmark.